KALM Therapeutics

Name

KALM Therapeutics

Legal name

KALM Therapeutics, Inc.

Website

https://kalmtherapeutics.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Dermatology Pharmaceuticals

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Contact Dermatitis & Patch Testing (HLAKACAK)

akta.pro secondary industries

Live Biotherapeutic Products (LBPs) (HLAAAFAA), Sensitive Skin & Barrier Repair (CRABAAAG)

Keywords

• Prescription dermatology therapeutics
• Topical drug delivery patches
• Eczema treatment development
• Psoriasis pharmaceutical研发
• Anti-inflammatory transdermal patches

Headquarters

HQ city

Huntsville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Prescription Pharmaceutical Sales: Revenue from selling prescription Kalm Patch (KP-77) for eczema and psoriasis treatment through pharmacy and healthcare provider channels after FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

KALM Therapeutics is developing the Kalm Patch (KP-77), a prescription topical patch that delivers a continuous 24-hour therapeutic dose of a plant-based, anti-inflammatory active pharmaceutical ingredient to treat eczema (atopic dermatitis) and psoriasis. The once-a-day patch simultaneously protects the affected skin from scratching, infection, and moisture loss while replacing the multiple daily applications of steroid creams that constitute the current standard of care.

Product overview

Kalm Therapeutics is developing a single prescription patch product called the Kalm Patch (KP-77) for the treatment of eczema and psoriasis. The product is a plant-based, anti-inflammatory patch that utilizes continuous dose technology to deliver medication over 24 hours, providing protection to affected skin while eliminating the need for multiple daily applications required by traditional steroid creams and topical treatments.

Differentiator

Problem solved

Functional benefit

Brands

• Kalm Patch: The Kalm Patch (KP-77) is the company's flagship prescription patch treatment for eczema and psoriasis, delivering continuous therapeutic dose over 24 hours with a plant-based active pharmaceutical ingredient.

Products and services

• Kalm Patch (KP-77) Prescription topical patch delivering a continuous 24-hour therapeutic dose of a plant-based, anti-inflammatory active pharmaceutical ingredient for the treatment of eczema (atopic dermatitis) and psoriasis. The once-a-day patch protects the skin from scratching, infection, and moisture loss while providing microbiome-balancing to reduce disease progression, and is currently in Phase 1b clinical trials.

Quantifiable outcome

• Once-a-day application vs 3-5 times daily for current standard of care
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Dermavant Sciences: Dermavant's Vtama (tapinarof) is a topical FDA-approved treatment for plaque psoriasis and atopic dermatitis — the most directly comparable prescription topical in Kalm's target indications. Dermavant was acquired by Organon for up to ~$1.2B, illustrating the commercial ceiling of differentiated topical dermatology assets.
• Arcutis Biotherapeutics: Arcutis is a clinical-to-commercial dermatology biotech developing next-generation topical therapies (e.g., Zoryve for atopic dermatitis and seborrheic dermatitis). Closely comparable as a small-cap, topical-focused dermatology developer pursuing steroid-replacement narratives.
• Pelthos Therapeutics (formerly Novan): Pelthos, the prior employer of Kalm's CMO Dr. Maeda-Chubachi, is a dermatology biotech that recently secured FDA approval for Zelsuvmi (molluscum contagiosum). It is a small specialty pharma with a comparable development-stage profile and a similar leadership pedigree.

Broad incumbents

• Sanofi / Regeneron (Dupixent): Dupixent (dupilumab) is the market-leading biologic for moderate-to-severe atopic dermatitis and a benchmark for any new eczema entrant. While a systemic biologic rather than a topical, Sanofi/Regeneron define the competitive standard Kalm must demonstrate superiority or meaningful convenience against.
• AbbVie (Rinvoq / Skyrizi): AbbVie's Rinvoq (upadacitinib) and Skyrizi (risankizumab) compete in moderate-to-severe atopic dermatitis and psoriasis. As a large incumbent with deep commercial reach, AbbVie represents the dominant competitive force in inflammatory skin disease.
• Pfizer (Eucrisa / Cibinqo): Pfizer's Eucrisa (crisaborole) is an FDA-approved topical PDE4 inhibitor for mild-to-moderate atopic dermatitis — a directly analogous topical competitor. Pfizer also markets Cibinqo (abrocitinib) for atopic dermatitis, adding an oral JAK competitor.
• Galderma: Galderma is one of the largest pure-play dermatology companies globally with a broad portfolio across eczema, psoriasis, and skin barrier disease. It serves as the archetypal incumbent that any prescription dermatology startup will eventually face in market access negotiations.
• LEO Pharma: LEO Pharma is a global dermatology specialist with established atopic dermatitis and psoriasis franchises (e.g., Adbry/adtralimumab). It is a representative incumbent peer for prescription dermatology development and commercialization.

Emerging players

• Evelo Biosciences: Evelo developed microbiome-based therapeutics for inflammatory diseases, including psoriasis. Comparable as an early-stage company pursuing microbiome-mediated mechanisms in skin inflammation — adjacent to Kalm's microbiome-balancing formulation claim.
• Siolta Therapeutics: Siolta is a clinical-stage microbiome therapeutics company developing live biotherapeutics for inflammatory diseases including atopic dermatitis. Comparable to Kalm's microbiome-balancing approach, though at a different stage and with a different therapeutic modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/in/company/kalm-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KALM Therapeutics